Positive single dose AB-729 data in chronic hepatitis B subjects supports  further clinical development First multiple dose cohort results expected in second half of 2020 One or more additional single dose cohorts planned to further optimize antiviral response and dosing frequency with results...

Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa. , March 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its fourth quarter and year end 2019 financial results, confirms 2020...

WARMINSTER, Pa. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and Year-End 2019 financial results, conference call and webcast for Thursday, March 5,...

Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation  (Nasdaq: ABUS), announced today its decision to discontinue AB-452, its first generation orally available hepatitis B (HBV) specific...

Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019 financial results and provides a corporate...

WARMINSTER, Pa. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for Wednesday, November 6, 2019 ....

WARMINSTER, Pa. , Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation  (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue the clinical development of AB-506, an oral capsid inhibitor....

WARMINSTER, Pa. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor conferences in October 2019 : Cantor...

WARMINSTER, Pa. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng , M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 17,...

WARMINSTER, Pa. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019...